Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

The Effect of Probiotic Supplementation on the Exercise Performance of Long-distance Runners.

NCT07411482 · tracked via the Priya Life Science Poland tracker
Phase
Not applicable
Started
2023-12-01
Last updated
2026-02-13

Condition(s) studied

Intestinal MicrobiomeProbioticRunners

Investigational drug(s) / intervention(s)

probiotics or placeboBox diet

probiotics or placebo: The study product is a probiotic mixture Sanprobi Active \& Sport, containing 2,5 x 109 CFU/g per capsule (≥500 million CFU in one capsule) of five strains of lactic acid bacteria (Bifidobacterium lactis W51, Lactobacillus brevis W63, Lactobacillus acidophilus W22, Bifidobacterium bifidum W23 and Lactococcus lactis W5); maize starch, maltodextrin, plant proteins and hydroxypropyl ethylcellulose tablets' coating. OR PLACEBo identically-looked

Box diet: To eliminate the effect of diet on the gut microbiome, all athletes received optimal, individually-balanced box-diet.

Study summary

The study is designed as a randomized double-blind placebo-controlled clinical trial with a 4-week probiotics intervention period. The study will be conducted between January 2022 and March 2025 at the Medical University of Gdańsk, Department of Bioenergetics and Physiology of Exercise (Gdańsk, Poland). A total of 40 endurance-trained adult men, specifically long-distance runners with previous experience in marathon races, will be enrolled. Only participants who meet all inclusion criteria and do not meet any exclusion criteria will be included in the study. Participants will be randomly assigned to the probiotic (PRO) or placebo (PL) group in a 1:1 ratio. Athletes will supplement 4 capsules of the study product (probiotic mixture) daily.

To eliminate the effect of diet on the gut microbiome, all athletes will receive an individually balanced box diet designed to provide 100% of energy requirements, protein intake of 1.6 g/kg/day, and at least 8 g/kg/day of carbohydrates. Participants will continue their training programs and perform at least 5 endurance workouts per week. To assess training loads, athletes will report average pulse range, subjective fatigue, and duration of training sessions.

The investigators will examine whether 4 weeks of probiotic supplementation in conjunction with a personalized diet may have a direct or indirect influence on sport performance. This will be assessed through evaluation of aerobic fitness capacity using treadmill tests. The cardiopulmonary exercise test (CPET) will determine maximum oxygen uptake, minute lung ventilation, and heart rate. Body composition analysis and assessments of blood and fecal samples will also be performed. Blood samples will be analyzed for serum pro-inflammatory cytokines (IL-6 and TNF-α). Collected fecal samples will be subjected to quantitative and qualitative analysis of the intestinal microbiota using next-generation sequencing. The analysis will include intestinal permeability markers (calprotectin, zonulin, IFABP) and bacterial metabolism products such as short-chain fatty acids (SCFA). All assessments and procedures will be carried out both before and immediately after the supplementation period.

All obtained data will undergo statistical analysis. Descriptive statistics will be used for background information and to examine trends in the analyzed parameters, with mean values and 95% confidence intervals. Depending on the distribution of the data, parametric or non-parametric tests will be applied. Statistical significance will be set at p \< 0.05.

To the best of the investigators' knowledge, this will be the first intervention study comprehensively assessing the influence of probiotic supplementation in conjunction with a standardized diet on inflammatory response, intestinal permeability, gut microbiome composition, and aerobic capacity of competitive long-distance runners. The collected data will provide evidence regarding the potential influence of probiotic supplementation on parameters of sport performance.

Eligibility

Sex
MALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Endurance-trained adult men (aged ≥ 18 years) * Long-distance runners with experience in at least three marathons or half-marathons * Average running speed between 10.549 and 14.065 km/h * At least 3 years of regular endurance training experience * Completion of 5 or more training sessions per week Exclusion Criteria: * Age below 18 years * Female gender * Antibiotic therapy within the last 3 months * Diagnosed inflammatory bowel disease * Chronic musculoskeletal injuries within the last 6 months * Heart failure or heart defects

Primary outcome measure(s)

  • The assessment of the impact of probiotic supplementation on maximal oxygen uptake value among athletes. — Baseline visit (before supplementation period) and after 4 weeks of supplementation period (post-intervention).
    Aerobic capacity will be assessed using an incremental treadmill test performed to volitional exhaustion. After a brief standing period on the treadmill to ensure stabilization of the measurement equipment, participants will complete a standardized low-intensity warm-up, followed by a stepwise increase in exercise intensity until exhaustion. Heart rate will be continuously monitored (Polar Electro Oy, Kempele, Finland), and respiratory variables (VO₂, VCO₂, VE, and RER) will be measured breath-by-breath using a calibrated metabolic cart (Oxycon Pro, Jaeger, Germany). Peak oxygen uptake (VO₂peak) will be defined as the highest value recorded during the test.
  • Analysis of gut microbiome — Baseline (pre-intervention) and after 4 weeks of supplementation (post-intervention).
    Fecal samples will be collected by participants before and after the 4-week intervention period using standardized containers. Samples will be immediately frozen at -80°C and analyzed by an independent laboratory. The intestinal microbiota will be assessed using next-generation sequencing of selected 16S rRNA gene regions. Microbiome composition will be characterized by alpha diversity (Chao1, ACE, Shannon, inverted Simpson) and beta diversity (Bray-Curtis and weighted UniFrac), and analyzed in relation to intestinal permeability markers (calprotectin, zonulin, IFABP) and bacterial metabolites (short-chain fatty acids, SCFA).

Trial sites (1)

FacilityCityRegionStatus
Medical University of Gdańsk Gdansk Poland
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07411482 on ClinicalTrials.gov ↗ ← All trials in Poland